ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Novavax (NVAX)
Novavax stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$10.02▲ +6.60%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Novavax in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Novavax
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Novavax a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $8.28 and $11.41; in 9 out of 10, between $6.23 and $15.18. Estimated annual volatility is 96%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $1.7B
- 52-week high
- $13.39
- 52-week low
- $6.20
- Revenue (12 months)
- $414M
- Revenue growth (YoY)
- +64.7%
- Gross margin
- 93.5%
- Operating margin
- 49.0%
- Net margin
- 39.2%
- Return on equity
- -344.7%
- Free cash flow (12 months)
- $153M
- Beta
- 2.45
What this means
ATLAS does not publish a fair value for NVAX right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks NVAX has traded between $6.20 and $13.39. Today it is 25.2% below that high and 62% above its low.
On the business: revenue grew 64.7% year over year; net margin is 39.2%.
Its beta is 2.45: it tends to move more than the market, both up and down.
About the company
Novavax Inc. is a biotechnology company focused on developing and commercializing vaccines that address serious infectious diseases.
Want to see everything about Novavax?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Novavax do?
Novavax Inc. is a biotechnology company focused on developing and commercializing vaccines that address serious infectious diseases.
What is the chance NVAX goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, NVAX ends the month between $8.28 and $11.41.
How big is Novavax and what is its P/E ratio?
Novavax's market capitalization is $1.7B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is NVAX?
ATLAS estimates annual volatility at 96%. In a typical month, half of the outcomes end between $8.28 and $11.41.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer